Table Graph
   

anti-inflammatory therapies - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.24 [0.01, 5.41]< 10%1 study (1/-)81.3 %NAnot evaluable crucial-
deaths 0.24 [0.01, 5.41]< 10%1 study (1/-)81.3 %NAnot evaluable crucial-
clinical deterioration 0.38 [0.09, 1.58]< 10%1 study (1/-)90.7 %NAnot evaluable important-
mechanical ventilation 0.24 [0.01, 5.41]< 10%1 study (1/-)81.3 %NAnot evaluable important-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %NAnot evaluable important-
ICU admission 0.47 [0.08, 2.69]< 10%1 study (1/-)80.1 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.24 [0.01, 5.41]< 10%1 study (1/-)81.3 %NAnot evaluable important-
adverse events 1.72 [0.73, 4.08]< 10%1 study (1/-)10.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons